Get the Stockscreener App
25.90
0.50%
-0.13
Zai Lab Limited Adr stock is traded at $25.90, with a volume of 1.23M.
It is down -0.50% in the last 24 hours and up +34.20% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
See More
Previous Close:
$26.03
Open:
$25.44
24h Volume:
1.23M
Relative Volume:
1.29
Market Cap:
$2.91B
Revenue:
$454.68M
Net Income/Loss:
$-178.68M
P/E Ratio:
-15.98
EPS:
-1.6209
Net Cash Flow:
$-135.66M
1W Performance:
+11.06%
1M Performance:
+34.20%
6M Performance:
+29.31%
1Y Performance:
-25.85%
1-Day Range:
$25.33
$26.26
1-Week Range:
$22.50
$26.66
52-Week Range:
$15.96
$36.77
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
899 HALEI ROAD, SHANGHAI
Compare ZLAB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
25.90 | 2.86B | 454.68M | -178.68M | -135.66M | -1.6209 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock - MarketBeat
William Lis Sells 8,506 Shares of Zai Lab (NASDAQ:ZLAB) Stock - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap DownWhat's Next? - MarketBeat
Zai Lab (ZLAB) insider William Lis plans sale of 8,506 ADS on NASDAQ - Stock Titan
Zai Lab (ZLAB) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Zai Lab Limited (ZLAB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
Zai Lab (ZLAB) Stock Jumps As Revenue Holds But Losses Deepen - Sahm
Zai Lab Q2 Earnings Call Highlights - Yahoo Finance
Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Form 8K ZAI LAB LIMITED For: 6 August By Investing.com - Investing.com Nigeria
Zai Lab (NASDAQ:ZLAB) Shares Up 14.5% on Strong Earnings - MarketBeat
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings - Yahoo Finance
Zai Lab (NASDAQ: ZLAB) expands pipeline as Q2 2026 loss reaches $50.8M - Stock Titan
Zai Lab (NASDAQ: ZLAB) posts Q2 2026 net loss of $50.8M - Stock Titan
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates - Business Wire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Zai Lab’s zoci targets previously treated neuroendocrine cancers - Stock Titan
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) - Business Wire
Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday - MarketBeat
UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB) - The Globe and Mail
ZLAB|Zai Lab Ltd|Price:23.320|Chg%:+2.440 - TradingKey
ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks - TradingView
A2DX1V Forecast — Price Target — Prediction for 2027 - TradingView
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 - BioSpace
Zai Lab schedules an Aug. 6 webcast and call for Q2 results - Stock Titan
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Zai Lab and Boehringer Advance New Immunotherapy Combo in Small Cell Lung Cancer - TipRanks
Director adds Zai Lab (ZLAB) ADS under pre-set Rule 10b5-1 plan - Stock Titan
Zai Lab (ZLAB) CEO Du Ying gains ADSs from RSU awards and tax withholding - Stock Titan
ZLABZai Lab Limited ADR Options - Finviz
Zai Lab stock keeps its listing focus. Investors watch the US ADR profile. - Ad-hoc-news.de
Zai Lab (ZLAB) CEO sells ADS to cover taxes after RSU vesting - Stock Titan
Form 144 Zai Lab Ltd For: 30 June By Investing.com - Investing.com Nigeria
ZLAB (NASDAQ: ZLAB) insider resale planned on 06/29/2026; recent ADS sales reported - Stock Titan
Zai Lab (ZLAB) legal chief settles RSUs, sells ADSs for taxes - Stock Titan
Zai Lab (ZLAB) CEO sells ADSs after RSU vesting and tax cover - Stock Titan
CFO equity transactions at Zai Lab (ZLAB) show RSU vesting and tax sale - Stock Titan
Zai Lab ADR outlines oncology pipeline priorities, shares tied to upcoming data - ad-hoc-news.de
1ZL Forecast — Price Target — Prediction for 2027 - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (GETTEX:1ZL) - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (LS:A2DX1V) - TradingView
Zai Lab Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ZLAB) - TradingView
Form 144 Zai Lab Ltd For: 26 June - Investing.com South Africa
Form 144 Zai Lab Ltd For: 26 June By Investing.com - Investing.com Nigeria
ZLAB (NASDAQ) director files to sell 2,264 ADS after vesting - Stock Titan
ZLAB (NASDAQ: ZLAB) director files Form 144 to sell 4,103 ADS on vesting - Stock Titan
ZLAB (NASDAQ: ZLAB) Form 144 shows Ying Du ADS sales and vesting event - Stock Titan
ZLAB/N Forecast — Price Target — Prediction for 2027 - TradingView
Zai Lab (ZLAB) director Lis sells 7,040 ADS under 10b5-1 plan - Stock Titan
Zai Lab (ZLAB) director receives 22,371 ADS restricted share grant - Stock Titan
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):